Key facts
- Amoneta Diagnostics’s last known valuation is $25.8M (Sep 2025).
- It has raised $6.7M; the latest was Later Stage VC ($4.2M) in Sep 2025.
- Notable investors include Alsace Business Angels, Alzheimers Drug Discovery Foundation, EuroTransBio, Eurostars.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Amoneta Diagnostics
- ·The full record, as it builds
Funding rounds
No funding rounds for Amoneta Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amoneta Diagnostics
Developer of biomarkers designed for the development of diagnostics in neurological diseases. The company seeks, develops and qualifies tests for Alzheimer's diagnosis under an exclusive license agreement with CNRS that can be performed on small blood samples using genuine fluorescent probes, which recognize biological markers specific for Alzheimer's patients, enabling medical practitioners to detect disease early and treat easily.
- Sector
- Healthcare
- HQ
- Huningue, France
- Founded
- 2014
- Employees
- 5
- Website
- amoneta-diagnostics.com/
- Ownership
- Privately Held (backing)
Amoneta Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amoneta Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amoneta Diagnostics in its N-PORT filings yet. We sweep new filings monthly.